Chan Ye Xin Xi Wang·2026-01-19 01:16Core Insights - The multi-valent vaccine market in China is experiencing growth, with a total of 127 batches approved in 2024, representing an 11% year-on-year increase [1] - The industry is characterized by significant advancements in technology and a shift towards multi-valent vaccines, which can prevent multiple diseases simultaneously [5][11] - Regulatory support and strategic policies are enhancing the development of the vaccine industry, emphasizing the importance of vaccine research and innovation [6] Multi-Valent Vaccine Overview - Multi-valent vaccines consist of multiple antigens to prevent various diseases, including both multi-valent and combination vaccines [3] - The market has seen a diversification of products, with several companies like Zhifei Biological and Kangtai Biological leading in the development of these vaccines [11][16] Batch Approval Data - In 2024, the approval of multi-valent vaccines included 127 batches, with specific increases in the three-valent (11%), four-valent (17%), and five-valent (10%) vaccines [1][12] - The first quarter of 2025 saw a decline in approvals, with a total of 17 batches, a 26% decrease compared to the previous year [1] Industry Development History - The Chinese vaccine industry has evolved from relying on single-valent vaccines to embracing multi-valent vaccines, marking a significant milestone in public health [5] - The introduction of the first domestically developed multi-valent vaccine by Kangtai Biological in 2011 was a pivotal moment for the industry [5] Policy Support - The Chinese government has implemented policies to support vaccine research and development, including the Vaccine Administration Law, which emphasizes the importance of vaccine innovation [6] - Recent notifications from health authorities indicate a structured approach to vaccine procurement and immunization program adjustments [6] Industry Chain - The multi-valent vaccine industry chain includes upstream raw materials, midstream research and production, and downstream sales and distribution [7] - Key players in the industry include Zhifei Biological, Kangtai Biological, and Sanofi Pasteur, which dominate the market in terms of batch approvals [16] Market Trends - Future developments in the multi-valent vaccine sector will be driven by technological innovations, including mRNA and modular vaccine designs [20] - There is a growing demand for vaccines tailored to specific demographics and health conditions, indicating a shift towards personalized healthcare solutions [21][22] - The production process is expected to become more automated and standardized, enhancing quality control and efficiency [23]